News-Medical.net - Clinical Trial To Evaluate IGF-1 In Children With SHANK3 Deficiency

 – April 25, 2012 /Press Release/  –– 

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency, a known cause of autism spectrum disorder (ASD). This study builds on findings announced by the researchers in 2010, which showed that after two weeks of treatment with IGF-1 in a mouse model, deficits in nerve cell communication were reversed and deficiencies in adaptation of nerve cells to stimulation, a key part of learning and memory, were restored. "This clinical trial is part of a paradigm shift to develop medications specifically to treat the core symptoms of autism, as opposed to medications that were developed for other purposes but were found to be beneficial for autism patients as well," said Joseph Buxbaum, PhD, Director of the Seaver Autism Center at Mount Sinai.
- Dr. Joseph Buxbaum, Professor, Psychiatry, Genetics and Genomic Sciences, Neuroscience, Director of the Seaver Autism Center, Mount Sinai School of Medicine
Learn more: http://www.news-medical.net/news/20120425/Clinical-trial-to-evaluate-IGF-1-in-children-with-SHANK3-deficiency.aspx